Get the Stockscreener App
17.60
0.17%
-0.03
After Hours:
17.66
0.06
+0.34%
Erasca Inc stock is traded at $17.60, with a volume of 2.24M.
It is down -0.17% in the last 24 hours and down -7.90% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$17.63
Open:
$18.41
24h Volume:
2.24M
Relative Volume:
0.47
Market Cap:
$6.16B
Revenue:
-
Net Income/Loss:
$-277.02M
P/E Ratio:
-18.87
EPS:
-0.9328
Net Cash Flow:
$-91.36M
1W Performance:
-3.72%
1M Performance:
-7.90%
6M Performance:
+29.32%
1Y Performance:
+1,000.00%
1-Day Range:
$16.88
$18.66
1-Week Range:
$16.88
$18.77
52-Week Range:
$1.3301
$24.28
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
17.60 | 5.97B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
HC Wainwright Has Negative Estimate for Erasca Q3 Earnings - MarketBeat
BofA Adjusts Price Target on Erasca to $20 From $18 - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim raises Erasca stock price target to $21 on pipeline progress - Investing.com Nigeria
Erasca Awards 1.3 Million Stock Options to New President of R&D - Kalkine Media
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.82, Implies 25% Upside - TradingView
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside - TradingView
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Erasca (NASDAQ:ERAS) Given New $22.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Erasca stock price target on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Erasca stock price target on trial progress - Investing.com
ERAS Maintained by HC Wainwright & Co. -- Price Target Raised to $22 - GuruFocus
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS - MarketBeat
Erasca (NASDAQ:ERAS) Announces Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Erasca Q2 EPS of $(0.14) misses $(0.11) estimate on R&D spend - scanx.trade
Earnings Flash (ERAS) Erasca Posts Q2 Loss $0.14 per Share, vs. FactSet Est of $0.11 Loss - marketscreener.com
Erasca, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ERAS: ERAS-0015 delivers strong efficacy and safety in RAS-mutant cancers, advancing toward pivotal trials - TradingView
Erasca Reports Second Quarter 2026 Business Updates and Financial Results - manilatimes.net
Erasca, Inc. 2Q 2026: Net income $(44.1M), EPS $(0.14) — 10-Q Summary - TradingView
Erasca (ERAS) boosts cash by $836M while advancing RAS oncology pipeline - Stock Titan
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation ... - Caledonian Record
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
ERAS DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
812,876 Shares in Erasca, Inc. $ERAS Acquired by Assenagon Asset Management S.A. - MarketBeat
Erasca appoints Charles Fuchs as R&D president By Investing.com - Investing.com India
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Eras - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - 巴士的報
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):